Drug profile

The FDA adverse-event record for Neomycin Sulfate; Nystatin; Thiostrepton; Triamcinolone Acetonide

11 FDA reports name Neomycin Sulfate; Nystatin; Thiostrepton; Triamcinolone Acetonide, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2482 of 2,679
by report volume (all drugs)
11
adverse-event reports
9.1%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Neomycin Sulfate; Nystatin; Thiostrepton; Triamcinolone Acetonide ranks #2412 of 2679 by total reports (11). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2412
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Neomycin Sulfate; Nystatin; Thiostrepton; Triamcinolone Acetonide has 11 reports now versus 11 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Neomycin Sulfate; Nystatin; Thiostrepton; Triamcinolone Acetonide changes

Signature read: 11 reports place Neomycin Sulfate; Nystatin; Thiostrepton; Triamcinolone Acetonide in the lower third of FDA AER volume (#2482 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
1
Deaths Reported
9.1%
Death-coded share of reports

Active Ingredients

Neomycin Sulfate; Nystatin; Thiostrepton; Triamcinolone Acetonide

Administration Routes

TopicalAuricular (Otic)Unknown

Species Affected

Dog 5
Unknown 3
Cat 3

Most Affected Breeds

Unknown 3
Newfoundland 2
Domestic Shorthair 2
Terrier - Yorkshire 1
Bulldog 1
Siamese 1
Spaniel (unspecified) 1

Most Reported Reactions

Pruritus 2
Tubes, Leaking 2
Deafness 2
Deafness NOS 1
Tubes, Abnormal 1
Periorbital oedema 1
Internal ear disorder 1
Crust 1
Pinnae disorder 1
Agitation 1
Vocalisation 1
Diarrhoea 1

Outcome Breakdown

Ongoing
3 (37.5%)
Outcome Unknown
2 (25.0%)
Recovered/Normal
2 (25.0%)
Euthanized
1 (12.5%)

Neomycin Sulfate; Nystatin; Thiostrepton; Triamcinolone Acetonide: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Neomycin Sulfate; Nystatin; Thiostrepton; Triamcinolone Acetonide (#2482 of 2,679 by report volume); death-coded 9.1%. PlainBreed drug row · report volume stamp 11 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →